Last reviewed 2026-04-20 · How we verify

Enzaprost (DINOPROST)

Enzaprost (DINOPROST) is a small molecule drug developed by PHARMACIA AND UPJOHN and currently owned by Pfizer. It targets the prostaglandin F2-alpha receptor and is classified as a dinoprost. Enzaprost is FDA-approved for various indications, including cervical ripening, hydatidiform mole, incomplete miscarriage, induction of labor, and pregnancy with abortive outcome. It is off-patent and has no active Orange Book patents, indicating that it is available as a generic medication. As a result, there are currently no generic manufacturers of Enzaprost.

At a glance

Approved indications

• Cervical ripening procedure
• Hydatidiform mole, benign
• Incomplete miscarriage
• Induction of labor
• Pregnancy with abortive outcome

Common side effects

• Any fetal heart rate abnormality
• Uterine contractile abnormality
• Any gastrointestinal effect
• Bradycardia
• Variable deceleration
• Back pain
• Late deceleration
• Unspecified deceleration
• Warm feeling in vagina
• Fever

Serious adverse events

• Uterine rupture
• Amnionitis
• Intrauterine fetal sepsis
• Premature rupture of membranes
• Fetal depression (1 min Apgar < 7)
• Fetal acidosis (umbilical artery pH < 7.15)
• Post-partum disseminated intravascular coagulation
• Anaphylactic reaction
• Anaphylactic shock
• Anaphylactoid reaction

Key clinical trials

• A Comparative Study of Intraocular Pressure Control Using Selective Laser Trabeculoplasty and Latanoprost as Initial Treatments for Primary Open Angle Glaucoma and Ocular Hypertension in Lagos State University Teaching Hospital (NA)
• A Clinical Trial Comparing the OMNI Surgical System to Standard Medical Treatment in Patients With Primary Open Angle Glaucoma (PHASE4)
• Safety and Efficacy Study of Topical DLQ01 in the Treatment of Androgenetic Alopecia (AGA) in Men (PHASE1,PHASE2)
• Oxidoreductive Balance and Lysosomal Activity in Cancer Patients.
• Prostaglandin F2-alpha (PGF2α) in Vitiligo (NA)
• Prostaglandin F2-alpha Eye Drops in Thyroid Eye Disease (Bima Study) (PHASE4)
• The Influence of Glycaemia and Insulinemia on Vasomotor Endothelial Function After Myocardial Infarction
• Techniques to Improve Efficacy of Second Trimester Medical Termination (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.